Data on drug prescriptions, diagnoses, and events are increasingly being used for epidemiologic and pharmacologic studies and for the evaluation of quality of care, but questions arise about how complete and accurate the diagnoses and events in these databases are.
Data on drug prescriptions, diagnoses, and events are increasingly being used for epidemiologic and pharmacologic studies and for the evaluation of quality of care, but questions arise about how complete and accurate the diagnoses and events in these databases are.
Therefore, Dutch researchers evaluated how well patients with major cardiovascular disease (CVD) hospitalizations can be identified from primary care data on morbidity and/or drug prescriptions in a regional database of patients with type 2 diabetes. The database included prescriptions, morbidity, lab test results, and physical exams. The researchers also evaluated the accuracy of using different drugs (platelet aggregation inhibitors, vitamin K antagonists, or nitrates) as proxies to identify patients with a history of major CVD and to identify a first major CVD event in patients without a history of CVD. The study, by Koen Bernardus Pouwels and colleagues from the University of Groningen, The Netherlands, was published in BMC Health Services Research.
The study used data from 17,230 diabetes patients from the GIANTT databases and Dutch Hospital Data register. At baseline, the mean age of the study population was 66 years; 48% were men, median diabetes duration was 6 years, and the prevalence of at least 1 major CVD diagnosis recorded by a general practitioner was 16%. The study period was January 1, 2008, to December 31, 2009. Only patients surviving the whole study period were included; the study did not assess fatal events.
Only 43% of major CVD hospitalizations could be identified using diagnoses recorded in primary care. Adding drug prescriptions to the search increased the sensitivity up to 94%. Using at least 1 prescription of either a platelet aggregation inhibitor, vitamin K antagonist, or nitrate as a proxy could identify 85% of patients with a history of major CVD recorded in primary care.
“Our finding that less than half of the hospitalizations for a major CVD were identified using primary care morbidity records indicates that even for major events such records are incomplete,” the authors concluded.
The finding that a large proportion of major CVD hospitalizations is not recorded in primary care morbidity data is particularly relevant in the context of upcoming regional and nationwide initiatives to improve electronic healthcare databases, they noted. Their findings stress the importance of combining different types of data and linking different data sources to identify patients with disease and using drug prescriptions as proxies to help identify patients with major CVD.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More